MGI/SuperGen’s Dacogen Is "Approvable" Pending Transfusion Data Analysis
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
MGI/SuperGen’s myelodysplastic syndromes therapy Dacogen (decitabine) is "approvable" at FDA pending submission of additional analysis of transfusion data
You may also be interested in...
MGI/SuperGen Estimate Dacogen Peak Sales Of $250 Mil.; Action Date Is Sept. 1
MGI and SuperGen estimate their myelodysplastic syndrome agent Dacogen has a market potential of $250 mil., SuperGen said July 21.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product